186 related articles for article (PubMed ID: 31990083)
1. Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data.
Papanikos T; Thompson JR; Abrams KR; Städler N; Ciani O; Taylor R; Bujkiewicz S
Stat Med; 2020 Apr; 39(8):1103-1124. PubMed ID: 31990083
[TBL] [Abstract][Full Text] [Related]
2. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
[TBL] [Abstract][Full Text] [Related]
3. Bivariate network meta-analysis for surrogate endpoint evaluation.
Bujkiewicz S; Jackson D; Thompson JR; Turner RM; Städler N; Abrams KR; White IR
Stat Med; 2019 Aug; 38(18):3322-3341. PubMed ID: 31131475
[TBL] [Abstract][Full Text] [Related]
4. Use of copula to model within-study association in bivariate meta-analysis of binomial data at the aggregate level: A Bayesian approach and application to surrogate endpoint evaluation.
Papanikos T; Thompson JR; Abrams KR; Bujkiewicz S
Stat Med; 2022 Nov; 41(25):4961-4981. PubMed ID: 35932152
[TBL] [Abstract][Full Text] [Related]
5. Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process.
Bujkiewicz S; Thompson JR; Riley RD; Abrams KR
Stat Med; 2016 Mar; 35(7):1063-89. PubMed ID: 26530518
[TBL] [Abstract][Full Text] [Related]
6. Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints.
Bujkiewicz S; Thompson JR; Spata E; Abrams KR
Stat Methods Med Res; 2017 Oct; 26(5):2287-2318. PubMed ID: 26271918
[TBL] [Abstract][Full Text] [Related]
7. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
8. Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials.
Su L; Chen X; Zhang J; Yan F
JCO Precis Oncol; 2022 Mar; 6():e2100394. PubMed ID: 35263169
[TBL] [Abstract][Full Text] [Related]
9. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
Odani M; Fukimbara S; Sato T
Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
[TBL] [Abstract][Full Text] [Related]
10. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints.
Chen N; Lee JJ
Stat Methods Med Res; 2020 Sep; 29(9):2717-2732. PubMed ID: 32178585
[TBL] [Abstract][Full Text] [Related]
11. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.
Li Y; Taylor JM; Elliott MR; Sargent DJ
Biostatistics; 2011 Jul; 12(3):478-92. PubMed ID: 21252079
[TBL] [Abstract][Full Text] [Related]
12. Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints.
Van der Elst W; Molenberghs G; Alonso A
Stat Med; 2016 Apr; 35(8):1281-98. PubMed ID: 26612787
[TBL] [Abstract][Full Text] [Related]
13. Improving the Estimation of Subgroup Effects for Clinical Trial Participants with Multimorbidity by Incorporating Drug Class-Level Information in Bayesian Hierarchical Models: A Simulation Study.
Hannigan LJ; Phillippo DM; Hanlon P; Moss L; Butterly EW; Hawkins N; Dias S; Welton NJ; McAllister DA
Med Decis Making; 2022 Feb; 42(2):228-240. PubMed ID: 34407672
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
Jiang Z; Song Y; Shou Q; Xia J; Wang W
Trials; 2014 Dec; 15():500. PubMed ID: 25528466
[TBL] [Abstract][Full Text] [Related]
15. A reflection on the causal interpretation of individual-level surrogacy.
Alonso A; Van Der Elst W; Molenberghs G; Florez AJ
J Biopharm Stat; 2019; 29(3):529-540. PubMed ID: 30773114
[TBL] [Abstract][Full Text] [Related]
16. Flexible evaluation of surrogacy in platform studies.
Sachs MC; Gabriel EE; Crippa A; Daniels MJ
Biostatistics; 2023 Dec; 25(1):220-236. PubMed ID: 36610075
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
Chu Y; Yuan Y
Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
[TBL] [Abstract][Full Text] [Related]
18. Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data.
Le Coënt Q; Legrand C; Rondeau V
Biostatistics; 2023 Dec; 25(1):98-116. PubMed ID: 36398615
[TBL] [Abstract][Full Text] [Related]
19. Bayesian hierarchical models for adaptive basket trial designs.
Chen C; Hsiao CF
Pharm Stat; 2023; 22(3):531-546. PubMed ID: 36625301
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the information theory approach to evaluating time-to-event surrogate and true endpoints in a meta-analytic setting.
Dimier N; Todd S
Pharm Stat; 2021 Mar; 20(2):335-347. PubMed ID: 33145928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
